Comparative immunological evaluation of recombinant Salmonella Typhimurium strains expressing model antigens as live oral vaccines

BMC Immunology

Jian-Dong Huang²  Kwok-Yung Yuen³  Bo-Jian Zheng³  Rory M Watt¹  Shuofeng Yuan³  Yan-Hong Hua²  Min Chen³  Ke Zhang³  Bin Yu²  Song-yue Zheng² 

[1] Oral Biosciences, Faculty of Dentistry, The University of Hong Kong, Prince Philip Dental Hospital, 34 Hospital Road, Sai Ying, Hong Kong;Department of Biochemistry, the University of Hong Kong, Pokfulam, Hong Kong;Department of Microbiology, the University of Hong Kong, Pokfulam, Hong Kong

关键词: Immunological comparison;    Construction strategies;    Soluble and insoluble antigens;    Live oral vaccine;    Salmonella Typhimurium;   

Others  :  1077875
DOI  :  10.1186/1471-2172-13-54

 received in 2012-03-12, accepted in 2012-09-04,  发布年份 2012

【 摘 要 】

Background

Despite the development of various systems to generate live recombinant Salmonella Typhimurium vaccine strains, little work has been performed to systematically evaluate and compare their relative immunogenicity. Such information would provide invaluable guidance for the future rational design of live recombinant Salmonella oral vaccines.

Result

To compare vaccine strains encoded with different antigen delivery and expression strategies, a series of recombinant Salmonella Typhimurium strains were constructed that expressed either the enhanced green fluorescent protein (EGFP) or a fragment of the hemagglutinin (HA) protein from the H5N1 influenza virus, as model antigens. The antigens were expressed from the chromosome, from high or low-copy plasmids, or encoded on a eukaryotic expression plasmid. Antigens were targeted for expression in either the cytoplasm or the outer membrane. Combinations of strategies were employed to evaluate the efficacy of combined delivery/expression approaches. After investigating in vitro and in vivo antigen expression, growth and infection abilities; the immunogenicity of the constructed recombinant Salmonella strains was evaluated in mice. Using the soluble model antigen EGFP, our results indicated that vaccine strains with high and stable antigen expression exhibited high B cell responses, whilst eukaryotic expression or colonization with good construct stability was critical for T cell responses. For the insoluble model antigen HA, an outer membrane expression strategy induced better B cell and T cell responses than a cytoplasmic strategy. Most notably, the combination of two different expression strategies did not increase the immune response elicited.

Conclusion

Through systematically evaluating and comparing the immunogenicity of the constructed recombinant Salmonella strains in mice, we identified their respective advantages and deleterious or synergistic effects. Different construction strategies were optimally-required for soluble versus insoluble forms of the protein antigens. If an antigen, such as EGFP, is soluble and expressed at high levels, a low-copy plasmid-cytoplasmic expression strategy is recommended; since it provokes the highest B cell responses and also induces good T cell responses. If a T cell response is preferred, a eukaryotic expression plasmid or a chromosome-based, cytoplasmic-expression strategy is more effective. For insoluble antigens such as HA, an outer membrane expression strategy is recommended.

【 授权许可】

   
2012 Zheng et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

Figure 2 .

Figure 3 .

Figure 4 .

Figure 5 .

【 参考文献 】

• [1]Chatfield SN, Dougan G, Schöde F, Levine MM, Galen JE, Sztein MB, Beier M, Noriega F: Attenuated Salmonella As a Live Vector for Expression of Foreign Antigens. second edn edition. New York: MARCEL DEKKER, INC; 1997.
• [2]Robert M, Chatfield SN, Dougan G: Salmonella as carriers of heterologous antigens. In Novel delivery systems for oral vaccines. Edited by Hagen DTO. CRC Press, Inc; 1994:27.
• [3]Medina E, Guzman CA: Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 2001, 19:1573-1580.
• [4]Shata MT, Stevceva L, Agwale S, Lewis GK, Hone DM: Recent advances with recombinant bacterial vaccine vectors. Mol Med Today 2000, 6:66-71.
• [5]Ravindran R, McSorley SJ: Tracking the dynamics of T-cell activation in response to Salmonella infection. Immunology 2005, 114:450-458.
• [6]Ulmer JB, Valley U, Rappuoli R: Vaccine manufacturing: challenges and solutions. Nat Biotechnol 2006, 24:1377-1383.
• [7]Nayak AR, Tinge SA, Tart RC, McDaniel LS, Briles DE, Curtiss RC: A live recombinant avirulent oral Salmonella vaccine expressing Pneumococcal surface protein A induce protective responses against Streptococcus pneumoniae. Infect Immun 1998, 66:3744-3751.
• [8]Liljebjelke KA, Petkov DI, Kapczynski DR: Mucosal vaccination with a codon-optimized hemagglutinin gene expressed by attentuated Salmonella elicits a protective immune response in chickens against highly pathogenic avian influenza. Vaccine 2010, 28:4430-4437.
• [9]Lee JS, Shin KS, Pan JG, Kim CJ: Surface-displayed viral antigens on Salmonella carrier vaccine. Nat Biotechnol 2000, 18:645-648.
• [10]Hone DM, Wu SG, Powell RJ, Pascual DW, Cott JV, McGhee J, Fouts TR, Tuskan RG, Lewis GK: Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses. J Biotechnol 1996, 44:203-207.
• [11]Luo FL, Feng Y, Liu M, Li PF, Pan Q, Jeza VT, Xia B, Wu JG, Zhang XL: Type IVB pilus operon promoter controlling expression of the severe acute respiratory syndrome-associated coronavirus nucleocapsid gene in Salmonella enterica serovar Typhi elicit full immune response by intranasal vaccination. Clin Vaccine Immunol 2007, 14:990-997.
• [12]Pan ZM, Zhang XM, Geng SZ, Cheng NN, Sun L: Priming with a DNA vaccine delivered by attenuated Salmonella typhimurium and boosting with a killed vaccine confers protection of chickens against infection with the H9 subtype of avian influenza virus. Vaccine 2008, 27:1018-1023.
• [13]Ning JF, Zhu W, Xu JP, Zheng CY, Meng XL: Oral delivery of DNA vaccine encoding VP28 against white spot syndrome virus in crayfish by attenuated Salmonella typhimurium. Vaccine 2009, 27:1127-1135.
• [14]Matic JN, Terry TD, Bockel DV, Maddocks T, Tinworth D, Jennings MP, Djordjevic SP, Walker MJ: Development of non-antibiotic-resistant, chromosomally based, constitutive and inducible expression systems for aroA-attentuated Salmonella enterica seroval typhimurium. Infect Immun 2009, 2009:1817-1826.
• [15]Gambotto A, Dworacki G, Cicinnati V, Kenniston T, Steitz J, Tuting T, Robbins PD: Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/C mice: identification of an H2-Kd-restricted CTL epitope. Gene therapy 2000, 7:2036-2040.
• [16]Chin'ombe N, Bourn WR, Williamson AL, Shephard EG: An oral recombinant Salmonella enterica serovar typhimurium mutant elicits systemic antigen-specific CD8+ T cell cytokine responses in mice. Gut Pathogens 2009., 1
• [17]Mayer MP: A new set of useful cloning and expression vectors derived from pBlueScript. Gene 1995, 163:41-46.
• [18]Datta S, Costantino N, Court D: A set of recombineering plasmids for gram-negative bacteria. Gene 2006, 379:109-115.
• [19]Ellermeier CD, Slauch JM: The Genus Salmonella. In The prokaryotes: a handbook on the biology of bacteria. Edited by Dworkin M, Falkow S. New York: Springer Science + Business Media, LLC; 2006:123-158.
• [20]Dikki JM, Chen XY, Shuai JB, Chen N, Fang WH: Attenuated Salmonella typhimurium as a carrier for prokaryotic and eukaryotic expression vectors. J Zhejiang University 2006, 32:237-244.
• [21]Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li SK, Xu MX, Penman S, Hoffman RM: Tumor-targeting bacterial therapy with amino acid auxotroph of GFP-expressing Salmonella typhimurium. PNAS 2005, 102:755-769.
• [22]Yu B, Yang M, Wang HY, Watt RM, Song E, Zheng BJ, Yuen KY, Huang JD: A method to generate recombinant Salmonella typhi Ty21a strain expressing multiple heterologous genes using an improved recombineering strategy. Appl Microbiol Botechnol 2011, 91:177-188.
• [23]Ashraf S, Kong W, Wang S, Yang J, Rr C: Protective cellular responses elicited by vaccination with influenza nucleoprotein delivered by a live recombinant attenuated Salmonella vaccine. Vaccine 2011, 29:3990-4002.
• [24]Wang S, Li Y, Shi H, Sun W, Roland KL, Curtiss R: Comparison of a regulated delayed antigen synthesis system within vivo-inducible promoters for antigen delivery by live attenuated Salmonella vaccines. Infect Immun 2011, 79:937-949.
• [25]Wolfenden RE, Layton SL, Wolfenden AD, Khatiwara A, Gaona-Ramirez G, Pumford NR, Cole K, Kwon YM, Tellez G, Bergman LR, et al.: Development and evaluation of candidate recombinant Salmonella-vecteroed Salmonella vaccines. Poult Sci 2010, 89:2370-2379.
• [26]Dunstan SJ, Simmons CP, Strugnell RA: In vitro and in vivo stability of recombinant plasmids in a vaccine strain of Salmonella enterica var. typhimurium. Medical Microbiology 2003, 37:111-119.
• [27]Mastroeni P, Maskell D: Salmonella Infections: Clinical, Immunological and Molecular Aspects. Cambridge University Press; 2006:337-355.
• [28]Cardenas L, Clements JD: Stability, immunogenicity and expression of foreign antigens in bacterial vaccine vectors. Vaccine 1993, 11:126-135.
• [29]Gentschev I, Sokolovic Z, Kohler S, Krohne GF, Hof H, Wagner J, Goebel W: Identification of p60 antibodies in human sera and presentation of this listerial antigen on the surface of attenuated salmonellae by the HlyB-HlyD secretion system. Infect Immun 1992, 60:5091-5098.
• [30]Tarkka E, Muotiala A, Karvonen M, Saukkonen LK, Sarvas M: Antibody production to a meningococcal outer membrane protein cloned into live Salmonella typhimurium aroA vaccine strain. Microb Pathog 1989, 6:327-335.
• [31]Coulson NM, Fulop M, Titball RW: Bacillus antracis protective antigen, expressed in Salmonella typhimurium SL3261, affords protection against anthrax spore challenge. Vaccine 1994, 12:1395-1401.
• [32]Coulson NM, Fulop M, Titball RW: Effect of different plasmids on colonization of mouse tissues by the aromatic amino acid dependent Salmonella typhimurium SL3261. Microb Pathog 1994, 16:305-311.
• [33]Jagusztyn-Krynicka EK, Clark-Curtiss JE, Curtiss R III: RC III: Escherichia coli heat-labile toxin subunit B fusions with Streptococcus sobrinus antigens expressed by Salmonella typhimurium oral vaccine strains: importance of the linker for antigenicity and biological activities of the hybrid protein. Infect Immun 1993, 61:1004-1015.
• [34]Turner SJ, Carbone FR, Strugnell RA: Salmonella typhimurium ΔaroA ΔaroD mutants expressing a foreign recombinant protein induce specific major histocompatibility complex class I-restricted cytotoxic T-lymphocytes in mice. Infect Immun 1993, 61:5374-5380.
• [35]Hone D, Attridge S, Lvd B, Hackett J: A chromosomal integration system for stabilization of heterologous genes in Salmonella based vaccine strains. Micro. Pathog 1988, 5:407-418.
• [36]Strugnell RA, Maskell D, Fairweather N, Pickard D, Cock-ayne A, Penn C, Dougan G: Stable expression of foreign antigens from the chromosome of Salmonella typhimurium vaccine strains. Gene 1990, 88:57-63.
• [37]Bauer H, Darji A, Chakraborty T, Weiss S: Salmonella-mediated oral DNA vaccination using stabilized eukaryotic expression plasmids. Gene Therapy 2005, 12:364-372.
• [38]Darji A, Sz L, Garbe AI, Chakraborty T, Weiss S: Oral delivery of DNA vaccines using attenuated Salmonella typhimurium as carrier. FEMS Immunol Med Microbiol 2000, 27:341-349.
• [39]Garmory HS, Titball RW, Brown KA, Bennett AM: Construction and evaluation of a eukaryotic expression plasmid for stable delivery using attenuated Salmonella. Microb Pathog 2003, 34:115-119.
• [40]Weiss S, Krusch S: Bacteria-mediated transfer of eukaryotic experssion plasmids into mammlian host cells. Biol Chem 2001, 382:533-541.
• [41]Brayden DJ, Jepson MA, Baird AW: Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting. Drug Discov. Today 2005, 10:1145-1157.
• [42]Loessner H, Weiss S: Bacteria-mediated DNA transfer in gene therapy and vaccination. Exp Opin Biol Ther 2004, 4:157-168.
• [43]Weiss S: Transfer of eukaryotic expression plasmids to mammalian hosts by attenuated Salmonella spp. Int J Med Microbiol 2003, 293:95-106.
• [44]Darji A, Guzman CA, Gerstel B, Wachholz P, Timmis KN, Wehland J: Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 1997, 91:765-775.
• [45]Sbdul-Wahid A, Faubert G: Mucosal delivery of a transmission-blocking DNA vaccine encoding Giardia lamblia CWP2 by Salmonella typhimurium bactorfection. Vaccine 2007, 25:8372-8383.
• [46]Woo PC, Wong LP, Zheng BJ, Yuen KY: Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium. Vaccine 2001, 19:2945-2954.
• [47]Hess J, Kaufmann SHE: Salmonella enterica infection. Elsevier: Science; 1996:581-586.
• [48]Crosby HA, Bion JF, Penn CW, Elliott TSJ: Antibiotic-induced release of endotoxin from bacteria in vitro. J Med Microbiol 1994, 40:23-30.
• [49]Martinez OV, Gratzner HG, Malinin TI, Ingram M: The effect of some β-lactam antibiotics on Escherichia coli. studied by flow cytometry. Cytometry 1982, 3:129-133.
• [50]Sykes RB, Bonner DP, Bush K, Georgopapadakou NH: Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria. Antimicrob Agents Chemother 1981, 21:85-92.
• [51]Silva F, Passarinha L, Sousa F, Queiroz JA, Domingues FC: Influence of growth conditions on plamsid DNA production. J Microbiol Biotechnol 2009, 19:1408-1414.
• [52]Ow DW, Nisson PM, Philp R, Oh SW, Oh SW, Yap MS: Global transcriptional analysis of metabolic burden due to plasmid maintenance in Escherichia coli DH5α during batch fermentation. Enzym Microb Technol 2005, 39:391-398.
• [53]Ricci JCD: Plamsid effects on Escherichia coli metabolism. Crit Rev Biotechnol 2000, 20:79-108.
• [54]Isoda R, Simanski SP, Pathangey L, Stone AE, Brown TA: Expression of Porphytomonas gingivalis hemagglutinin on the surface of a Salmonella vaccine vector. Vaccine 2007, 25:117-126.
• [55]Hoiseth SK, Stocker BA: Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 1981, 291:238-9.
• [56]Hensel M: Salmonella Pathogenicity Island 2. Mol Microbiol 2000, 36:1015-1023.
• [57]Jin Y, Watt RM, Danchin A, Huang JD: Small noncoding RNA GcvB is a novel regulator of acid resistance in Escherichia coli. BMC Genomics 2009., 10City
• [58]Abramoff MD, Magelhaes PJ, Ram SJ: Image Processing with Image J. Biophotonics Int 2004, 11:36-42.
• [59]Specter S, Hodinka RL, Young SA, Wiedbrauk DL: Clinical Virology Manual. 3rd edition. Washington, D.C.: ASM Press; 2000.